GelStat Corp.

GSAC

US3685331056

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 03:20:31 2024-04-29 pm EDT			5-day change	1st Jan Change
0.0003 ^USD	-25.00%		-25.00%	0.00%

2023	GelStat Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	GelStat Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

GelStat Corporation Auditor Raises 'Going Concern' Doubt

May 01, 2022

GelStat Corporation filed its 1-K on May 02, 2022 for the period ending Dec 31, 2021. In this report its auditor, Ciro E. Adams, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about GelStat Corp.

GelStat Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
GelStat Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-12	CI
GelStat Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-10	CI
GelStat Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-10-03	CI
GelStat Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-02	CI
GelStat Corporation Auditor Raises 'Going Concern' Doubt	22-05-01	CI
GelStat Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-24	CI
GelStat Corp. Auditor Raises 'Going Concern' Doubt	21-10-28	CI
GelStat Corporation Announces Management Changes	15-11-16	CI
GelStat Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for 2015	15-04-16	CI
GelStat Corp. Announces Consolidated Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for 2015	15-03-03	CI
GelStat Corporation Reports Consolidated Earnings Results for the Third Quarter Ended September 30, 2014; Provides Revenue Guidance for the Fourth Quarter Ending December 31, 2014	14-11-17	CI
GelStat Corporation Reports Consolidated Revenue Results for the Third Quarter Ended September 30, 2014; Revises Revenue Guidance for the Fourth Quarter Ending December 31, 2014	14-10-27	CI
GelStat Corporation Signs Distribution Agreement with Next Distributors, LLC	14-09-29	CI
GelStat Corp. Reports Revenue Results for the Second Quarter Ended June 30, 2014; Provides Revenue Guidance for the Third and Fourth Quarters of 2014	14-08-19	CI
GelStat Corp. completed the acquisition of Mastix Medica LLC.	14-07-07	CI
GelStat Corporation Signs Distribution Agreement with Windmill Health Products for the Distribution of 'Chews 2 Lose' Appetite Suppressant Gum	14-06-24	CI
GelStat Corp. signed a definitive agreement to acquire Mastix Medica LLC for $1.4 million.	14-06-05	CI
GelStat Corporation Launches Chews 2 Lose, its New Appetite Suppressant Gum	14-04-29	CI
GelStat Corporation Names Roger Cady as Chief Medical Advisor	14-04-01	CI
GelStat Corporation Receives Initial Purchase Order from Windmill Health Products	14-01-27	CI
GelStat Corporation Announces Executive Changes	13-10-23	CI
GelStat Corp. completed the acquisition of CBD LIFE SCIENCES, INC. from Larry Gershman.	13-10-23	CI
GelStat Corp. entered into a letter of intent to acquire CBD LIFE SCIENCES, INC. from Larry Gershman.	13-06-10	CI
GelStat Corp. Announces Executive Changes	13-06-09	CI

Chart GelStat Corp.

Duration

Period

More charts

Company Profile

GelStat Corporation is engaged in research, development, marketing and branding of advanced technology operations. The Company's subsidiary, GSAC Engineering Corporation, is engaged in the development of technologies for clean energy and industrial security. The Company has acquired the intellectual property of Duos Technologies Group, Inc.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GELSTAT CORP.	0.00%	1.2M
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B